On Oct 12 Jindike shares hit the daily limit down after reports the stock could face a delisting-risk warning. The company’s board secretary office said it has timely disclosed required information to the CSRC and Shanghai Stock Exchange and has no other undisclosed material information. Jindike said its trivalent influenza vaccine has entered secondary packaging; commercial sales timing will depend on batch-release progress. On whether the quadrivalent vaccine is being paused temporarily or dis

On Oct 12 Jindike shares hit the daily limit down after reports the stock could face a delisting-risk warning. The company’s board secretary office said it has timely disclosed required information to the CSRC and Shanghai Stock Exchange and has no other undisclosed material information. Jindike said its trivalent influenza vaccine has entered secondary packaging; commercial sales timing will depend on batch-release progress. On whether the quadrivalent vaccine is being paused temporarily or discontinued, the company said WHO issues H2 Northern Hemisphere influenza guidance early each year and China CDC issues vaccination guidance in July–August, and decisions will be made based on that year’s situation.